Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Pulmonary edema is a condition caused by an accumulation of fluid in the lungs. This fluid accumulates in the lungs' numerous air sacs, making breathing difficult. Pulmonary edema is classified into two types based on where the accumulation of fluid begins in our body. Cardiogenic pulmonary edema occurs, when it is caused by a heart problem such as heart failure. A heart failure usually causes edema in the lungs. Non-cardiogenic pulmonary edema is caused by non-heart conditions such as acute respiratory distress syndrome (ARDS) or high-altitude pulmonary edema (HAPE). Pulmonary edema can sometimes be caused by both heart as well as a non-heart conditions.

The first line of treatment for acute pulmonary edema include supplemental oxygen, which is typically administered through an nasal cannula, a flexible plastic tube with two openings that deliver oxygen to each nostril. Depending on the extent of the condition and the cause of the pulmonary edema, some medications such as diuretics, blood pressure medications, morphine, or inotropes may be prescribed.

Global Pulmonary Edema Therapeutics Market – Dynamics

The increasing prevalence of heart failure, a major cause of pulmonary edema is expected to propel growth of the global pulmonary edema therapeutics market. For instance, according to the Centers for Disease Control and Prevention, in 2020, around 6.2 million adults in the U.S. had heart failure. Moreover, in 2018, heart failure was mentioned on 379,800 death certificates (13.4%) in the U.S.

Recent product launches and approvals is expected to boost global pulmonary edema therapeutics market growth. For instance, on May 5, 2020, Farxiga (dapagliflozin), an oral tablet developed by AstraZeneca, a global biopharmaceutical company, was approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with reduced ejection fraction. Heart failure is a severe condition, which leads to cardiogenic pulmonary edema. These factors are expected to support global pulmonary edema therapeutics market growth over the forecast period.

Global Pulmonary Edema Therapeutics Market – Regional Insights

Among regions, North America is expected to account for the largest share in global pulmonary edema therapeutics market during the forecast period, owing to the recent approvals for the treatment of heart failure, a major cause for pulmonary edema. For instance, on May 08, 2020, Amgen Inc. and Cytokinetics Inc. who had collaborated, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as cardiac myotrope, is being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Heart failure is a severe condition, which leads to cardiogenic pulmonary edema. Amgen Inc. is U.S.-based multinational biopharmaceutical company, which manufactures biologic therapies for serious illnesses like cancer and cardiovascular diseases. Cytokinetics is a late-stage biopharmaceutical company specializing in the discovery, development, and commercialization of first-in-class muscle activators.

Moreover, due to increasing collaborations and sales partnerships, Europe may witness a lucrative growth in global pulmonary edema therapeutics market over the forecast period. For instance, on November 19, 2020, Novartis International AG, one of the leading pharmaceutical company, announced an exclusive global license and collaboration agreement with Mesoblast to develop, commercialize, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. Remestemcel-L is an investigational therapy that consists of culture-expanded mesenchymal stromal cells derived from an unrelated donor's bone marrow. Acute respiratory distress syndrome (ARDS) is one of the major non-heart related problems that leads to non-cardiogenic pulmonary edema. Mesoblast Ltd. is a company, which develops treatments for inflammatory ailments, cardiovascular disease, and back pain. These factors are expected to support global pulmonary edema therapeutics market growth over the forecast period.

Global Pulmonary Edema Therapeutics Market    – Taxonomy

By Drug Class:

  • Diuretics
  • Opioid Analgesics
  • Vasodilators
  • Inotropes
  • Others

By Type:

  • Cardiogenic Pulmonary Edema
  • Non-cardiogenic Pulmonary Edema

By Route of Administration:

  • Oral
  • Intravenous

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Global Pulmonary Edema Therapeutics Market – Competitive landscape

Key players operating in the global pulmonary edema therapeutics market include Novartis International AG, Cytokinetics Inc., Amgen Inc., AstraZeneca plc., Celularity Inc., and United Therapeutics Corporation.

N/A
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.